Treating Pain in Diabetic Neuropathy: Current and Developmental Drugs
The DOI matches its Crossref record; 248 of the 249 references it cites were found in a registry or an index.
Abstract
There is a high prevalence of painful diabetic polyneuropathy (pDPN) with around one-third of all patients with diabetes suffering from pDPN. pDPN has debilitating consequences, with a major impact on morbidity and quality of life. Unfortunately, there is no globally licenced pharmacotherapy that modulates the underlying disease mechanisms to prevent or halt the progression of diabetic neuropathy. The cornerstone of treatment therefore remains optimising glycaemic control and cardiovascular risk factors, and symptom control. Evidence from placebo-controlled studies has shown that antidepressants and anticonvulsants are effective for alleviating pDPN. Current clinical guidelines recommend the treatment of pDPN through the use of amitriptyline (tricyclic antidepressant), duloxetine (serotonin norepinephrine reuptake inhibitor), gabapentin and pregabalin (α2-δ ligands), tramadol and tapentadol (μ receptor agonists and norepinephrine reuptake inhibitors) and topical agents such as capsaicin (transient receptor potential V1 receptor desensitizer), although the latter is known to cause degeneration of small nerve fibers. pDPN can be difficult to treat, which frustrates healthcare providers, patients and caregivers. There is an additional need for clinical trials of novel therapeutic agents and optimal combinations for the management of pDPN. This article reviews the pharmacological management of pDPN, emerging therapies, the difficulties of placebo response in clinical trials and n…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The earliest affected nerve fibers are usually the small myelinated and unmyelinated fibers; thus, the most common early symptoms are pain and dysesthesias (unpleasant sensations of burning).547,554,555”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [554]
In the citing paper
“The earliest affected nerve fibers are usually the small myelinated and unmyelinated fibers; thus, the most common early symptoms are pain and dysesthesias (unpleasant sensations of burning).547,554,555”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [554]
In the citing paper
“Electrophysiological testing or referral to a neurologist is rarely needed for diagnosis, except in situations where the clinical features are atypical, the diagnosis is unclear, and a different etiology is suspected.547,554,565”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [554]
In the citing paper
“Moderate improvements in pain are considered to be approximately 30–50% pain relief, whereas a good outcome is considered greater than 50% pain relief [10].”
Citations
Cites
Items 201–248 of 248
Vinik, A., Emir, B., Parsons, B., & Cheung, R. (2014) · Pain Medicine · doi:10.1111/pme.12310 · Cited by 51 · cited 1×
“In fact, a large percentage of improvement in pDPN is thought to be associated with improvements via an indirect effect of improving sleep [86].”
BackgroundHydromorphone for neuropathic pain in adults
Stannard, C., Gaskell, H., Derry, S., Aldington, D. J., Cole, P., Cooper, T. E., Knaggs, R., Wiffen, P. J., & Moore, R. A. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011604.pub2 · Cited by 51
Thibault, K., Bonnard, E., Dubacq, S., Fournié‐Zaluski, M., Roques, B. P., & Calvino, B. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.10.004 · Cited by 51 · cited 1×
“An experimental rodent model showed the increase in endogenous enkephalin levels induced by PL37 reduced neuropathic pain [214].”
BackgroundRayman, G., Baker, N. R., & Krishnan, S. T. M. (2003) · Diabetes Care · doi:10.2337/diacare.26.9.2697-a · Cited by 50 · cited 1×
“determined a reduction in local pain scores in a case series of patients (N = 18) treated with 5 mg glyceryl-trinitrate (GTN) patches applied to the shins [182].”
MethodPredictors of Placebo Response in Pooled Lamotrigine Neuropathic Pain Clinical Trials
Irizarry, M. C., Webb, D. J., Ali, Z., Chizh, B. A., Gold, M., Kinrade, F. J., Meisner, P. D., Blum, D., Silver, M. T., & Weil, J. G. (2009) · The Clinical Journal of Pain · doi:10.1097/ajp.0b013e31819ddded · Cited by 48 · cited 1×
“However, placebo response was evaluated in three trials of lamotrigine (N = 252 placebo; N = 222 pDPN) [239].”
BackgroundShaibani, A. I., Pope, L. E., Thisted, R., & Hepner, A. (2012) · Pain Medicine · doi:10.1111/j.1526-4637.2011.01316.x · Cited by 48 · cited 1×
“Subsequently, a 13-week, phase 3 RCT (N = 379) included subjects with pDPN who received placebo, DMQ 45/30 mg or DMQ 30/30 mg [218].”
BackgroundDuloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in China.
Gao, Y., Ning, G., Jia, W., Zhou, Z., Xu, Z.-R., Liu, Z.-M., Liu, C., Ma, J., Li, Q., Cheng, L. L., et al. (2010) · PubMed · Cited by 47
The Role of Sodium Channels in Painful Diabetic and Idiopathic Neuropathy
On behalf of the PROPANE Study group, Lauria, G., Ziegler, D., Malik, R. A., Merkies, I. S. J., Waxman, S. G., & Faber, C. G. (2014) · Current Diabetes Reports · doi:10.1007/s11892-014-0538-5 · Cited by 46 · cited 1×
“Sodium channel therapeutic targets provide a novel approach to the treatment of pDPN [205].”
BackgroundChannelopathies, painful neuropathy, and diabetes: which way does the causal arrow point?
Hoeijmakers, J. G. J., Faber, C. G., Merkies, I. S. J., & Waxman, S. G. (2014) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.06.003 · Cited by 44
Sadosky, A., Hopper, J., & Parsons, B. (2014) · The Patient - Patient-Centered Outcomes Research · doi:10.1007/s40271-013-0038-8 · Cited by 42 · cited 1×
“[26] also reported significant clinical misperceptions by healthcare professionals in the perceived prevalence of pDPN compared to actual estimates reported by patients.”
ResultNaVchannel variants in patients with painful and nonpainful peripheral neuropathy
Wadhawan, S., Pant, S., Golhar, R., Kirov, S. A., Thompson, J., Jacobsen, L., Qureshi, I., Ajroud‐Driss, S., Freeman, R. L., Simpson, D. M., et al. (2017) · Neurology Genetics · doi:10.1212/nxg.0000000000000207 · Cited by 41 · cited 1×
“A gain of function in the ‘gatekeeper’ sodiumv channels has been reported in a significant proportion of pDPN patients [173].”
BackgroundPatil, P. R., Wolfe, J., Said, Q., Thomas, J., & Martin, B. C. (2014) · Clinical Journal of Pain · doi:10.1097/ajp.0000000000000124 · Cited by 41 · cited 1×
“Another retrospective study suggested that over half of patients with diabetes were receiving no physician-prescribed treatment in the year following diagnosis of DPN, 54% of those who subsequently received treatment were prescribed opioids and 33% were given the opioid as first-line treatment [161].”
BackgroundPregabalin as a Treatment for Painful Diabetic Peripheral Neuropathy: A Meta-Analysis
Hurley, R. W., Lesley, M. R., Adams, M. C. B., Brummett, C. M., & Wu, C. L. (2008) · Regional Anesthesia & Pain Medicine · doi:10.1016/j.rapm.2008.02.012 · Cited by 40
ZHANG, S. ‐., WU, Z., ZHANG, L. ‐., ZHANG, Z., CHEN, R. ‐., HUANG, Y. ‐., & CHEN, H. (2015) · Acta Anaesthesiologica Scandinavica · doi:10.1111/aas.12420 · Cited by 39
Fentanyl for neuropathic pain in adults
Derry, S., Stannard, C., Cole, P., Wiffen, P. J., Knaggs, R., Aldington, D., & Moore, R. A. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011605.pub2 · Cited by 39
Moulin, D. E., Morley-Forster, P., Pirani, Z., Rohfritsch, C., & Stitt, L. (2019) · Canadian Journal of Anesthesia/Journal canadien d anesthésie · doi:10.1007/s12630-019-01395-8 · Cited by 39 · cited 1×
“However, the most recent study of IV lidocaine in an RCT assessing its efficacy in painful neuropathy showed no additional analgesic benefit when compared to the control infusion [198].”
BackgroundDworkin, R. H., Turk, D. C., Peirce-Sandner, S., McDermott, M. P., Farrar, J. T., Hertz, S., Katz, N. P., Raja, S. N., & Rappaport, B. A. (2010) · Pain · doi:10.1016/j.pain.2010.02.002 · Cited by 38
Huffman, C., Stacey, B. R., Tuchman, M., Burbridge, C., Li, C., Parsons, B., Pauer, L., Scavone, J. M., Behar, R., & Yurkewicz, L. (2015) · The Clinical Journal of Pain · doi:10.1097/ajp.0000000000000198 · Cited by 37
INTRODUCTORY ADDRESS TO THE DISCUSSION ON THE CLINICAL ASPECT OF GLYCOSURIA.
Pavy, F. (1885) · The Lancet · doi:10.1016/s0140-6736(00)33144-0 · Cited by 37
Desipramine for neuropathic pain in adults
Hearn, L., Moore, R. A., Derry, S., Wiffen, P. J., & Phillips, T. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011003 · Cited by 37
Tanenberg, R. J., Clemow, D. B., Giaconia, J. M., & Risser, R. C. (2013) · Pain Practice · doi:10.1111/papr.12121 · Cited by 36 · cited 10×
“Small placebo-controlled RCTs have found amitriptyline to be superior to placebo; however, in two of these studies the dose used was over the recommended prescribing doses in current clinical practice (> 100 mg/day) [74, 103–105].”
BackgroundInfluentialMu, Y., Liu, X.-M., Li, Q., Chen, K., Liu, Y., Lv, X., Xu, X., Fan, D., Shang, N., Yang, R., et al. (2017) · Journal of Diabetes · doi:10.1111/1753-0407.12585 · Cited by 36
Mirogabalin and emerging therapies for diabetic neuropathy
Javed, S., Alam, U., & Malik, R. A. (2018) · Journal of Pain Research · doi:10.2147/jpr.s145999 · Cited by 36 · cited 5×
“It was initially licenced/marketed in Japan and now is available in other counties such as India and China.”
BackgroundResultInfluentialSelf-citationFink, J., Freeman, R., Emir, B., & Parsons, B. (2015) · Journal of Pain Research · doi:10.2147/jpr.s78303 · Cited by 35 · cited 3×
“[237] evaluated patient-level data from 16 double-blind RCTs of pregabalin in pDPN (N = 3053) and postherpetic neuralgia (N = 1460).”
BackgroundMethodInfluentialEMA401: an old antagonist of the AT2R for a new indication in neuropathic pain
Hesselink, J. K., & Schatman, M. E. (2017) · Journal of Pain Research · doi:10.2147/jpr.s128520 · Cited by 34 · cited 1×
“antagonist that is being developed for the treatment of neuropathic pain, pDPN, postherpetic neuralgia and inflammatory pain indications [209].”
BackgroundCapsaicin – an effective topical treatment in pain
Markovits, E., & Gilhar, A. (1997) · International Journal of Dermatology · doi:10.1046/j.1365-4362.1997.00102.x · Cited by 34 · cited 1×
“The depletion of substance P and desensitisation of TRPV1 causes a reduction of painful stimuli [183, 184].”
BackgroundRolim, L. C., da Silva, E. M. K., de Sá, J. R., & Dib, S. A. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00285 · Cited by 34 · cited 3×
“[254], four RCTs were identified and investigated with three main results in relation pain phenotypes.”
BackgroundIntravenous Novocaine for Analgesia in Burns: (A Preliminary Report).
GORDON, R. A. (1943) · PubMed · Cited by 33
Nenke, M. A., Haylock, C. L., Rankin, W., Inder, W. J., Gagliardi, L., Eldridge, C., Rolan, P., & Torpy, D. J. (2015) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2015.03.015 · Cited by 32 · cited 1×
“This condition can be life threatening, with opioid-induced adrenal insufficiency occurring in up to 29% of people on long-term opioids [158].”
BackgroundThisted, R. A., Klaff, L. J., Schwartz, S. L., Wymer, J. P., Culligan, N. W., Gérard, G., Pope, L. E., & Berg, J. E. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.10.005 · Cited by 31 · cited 1×
“In an early open-label multicentre doseescalation study (max DMQ 120/120 mg in increments of 30/30 mg), improvements were seen in pain intensity-rating and pain relief-rating scales [217].”
BackgroundHan, T., Bai, J., Liu, W., & Hu, Y. (2012) · Cited by 30
The International Association for the Study of Pain (IASP) Classification of Chronic Pain Syndromes
Kennedy, R. E., & Abd-Elsayed, A. A. (2019) · Springer eBooks · doi:10.1007/978-3-319-99124-5_234 · Cited by 30 · cited 1×
“The International Association for the Study of Pain (IASP) defines neuropathic pain as “pain initiated or caused by a primary lesion or dysfunction in the nervous system” [27].”
BackgroundEnomoto, H., Yasuda, H., Nishiyori, A., Fujikoshi, S., Furukawa, M., Ishida, M., Takahashi, M., Tsuji, T., Yoshikawa, A., & Alev, L. (2018) · Journal of Pain Research · doi:10.2147/jpr.s170646 · Cited by 29 · cited 1×
“However, other studies have found duloxetine to have similar or inferior efficacy to pregabalin and/or gabapentin [56, 74, 131, 132].”
BackgroundGabapentin therapy for diabetic neuropathic pain
Pérez, H. E. T., & Sánchez, G. F. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(00)00398-3 · Cited by 28 · cited 1×
“Further smaller studies have found gabapentin to be more effective than placebo at maximum doses of 1200 mg [48] and 3600 mg [49], but not 900 mg/day [50].”
BackgroundSerpell, M. G., Latymer, M., Almas, M., Ortiz, M., Parsons, B., & Prieto, R. (2017) · Journal of Pain Research · doi:10.2147/jpr.s129832 · Cited by 28
Wernicke, J., Raskin, J., Rosen, A. S., Pritchett, Y., D’Souza, D. N., Iyengar, S., Knopp, K. L., & Le, T. K. (2006) · Current Therapeutic Research · doi:10.1016/j.curtheres.2006.10.001 · Cited by 26
Raskin, P., Huffman, C., Yurkewicz, L., Pauer, L., Scavone, J. M., Yang, R., & Parsons, B. (2016) · The Clinical Journal of Pain · doi:10.1097/ajp.0000000000000254 · Cited by 25
Tavakoli, M., Asghar, O., Alam, U., Petropoulos, I. N., Fadavi, H., & Malik, R. A. (2010) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018810370954 · Cited by 25 · cited 1×
“Despite the FDA requiring trials of at least 20 weeks to determine analgesic efficacy, there is little indication that the placebo response reaches a plateau even by 19 weeks [241, 242].”
BackgroundSelf-citationLampl, C., Schweiger, C., Haider, B., & Lechner, A. (2010) · Journal of Neurology · doi:10.1007/s00415-010-5504-9 · Cited by 22 · cited 1×
“4–14) with pregabalin 600 mg per day [77, 85].”
BackgroundParsons, B., & Li, C. (2016) · Current Medical Research and Opinion · doi:10.1185/03007995.2016.1151776 · Cited by 20
Juhn, M. S., Parsons, B., Varvara, R., & Sadosky, A. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1030375 · Cited by 18 · cited 5×
“Pregabalin may be initiated at 75 mg twice per day and the maximal approved dose for the treatment of pDPN is 300 mg in the USA and 600 mg in Europe [59].”
BackgroundInfluentialSmith, T. R., DiBernardo, A., Shi, Y., Todd, M. J., Brashear, H. R., & Ford, L. (2013) · Pain Practice · doi:10.1111/papr.12080 · Cited by 15
The Placebo Response: Relationship to Outcomes in Trials of Postherpetic Neuralgia
Irving, G. A. (2010) · Clinical Drug Investigation · doi:10.2165/11584300-000000000-00000 · Cited by 12
Opioids before and after initiation of pregabalin in patients with diabetic peripheral neuropathy
Kozma, C. M., Benson, C. J., Slaton, T. L., Kim, M. S., & Vorsanger, G. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.713338 · Cited by 10 · cited 5×
“Pregabalin may be initiated at 75 mg twice per day and the maximal approved dose for the treatment of pDPN is 300 mg in the USA and 600 mg in Europe [59].”
BackgroundInfluentialPL37: a new Hope in the Treatment of Painful Diabetic Neuropathy?
Tesfaye, S. H. (2016) · Pain Management · doi:10.2217/pmt.15.68 · Cited by 9 · cited 1×
“PL37 is the first orally administered dual inhibitor of enkephalinases (DENKI) [213].”
BackgroundSelf-citationParsons, B., & Emir, B. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.03.019 · Cited by 8 · cited 3×
“Despite pregabalin being associated with weight gain, Parsons et al. performed a pooled-analysis on data from 11 double-blind RCTs and found no clinically meaningful effect of pregabalin on metabolic parameters such as HbA1c [89].”
MethodSelvarajah, D., Heiberg-Gibbons, F., Wilkinson, I. D., Gandhi, R. A., & Tesfaye, S. H. (2018) · Diabetes · doi:10.2337/db18-550-p · Cited by 7
Self-citationSelvarajah, D., Awadh, M., Gandhi, R. A., Wilkinson, I. D., & Tesfaye, S. H. (2018) · Diabetes · doi:10.2337/db18-61-or · Cited by 5 · cited 1×
“There are additionally abnormal cortical interactions within the somato-motor network that correlate with pain and behaviour in pDPN [250].”
BackgroundSelf-citation
Research works printed but not linked: 7
- IDF. IDF diabetes atlas. 8th Edition ed: Web; 2017.
- Sansone RA, Sansone LA. Serotonin norepinephrine reuptake inhibitors: a pharmacological comparison. Innov Clin Neurosci. 2014;11(3–4):37–42.
- Iqbal Z, Azmi S, Yadav R, Ferdousi M, Kumar M, Cuthbertson DJ, et al. Diabetic peripheral neuropathy: epidemiology, diagnosis, and pharmacotherapy. Clin Ther. 2018;40(6):828–49. · DOI · Paper page
- McNicol ED, Midbari A, Eisenberg E. Opioids for neuropathic pain. Cochrane Database Syst Rev. 2013(8). · DOI · Paper page
- Wolff RF, Bala MM, Westwood M, Kessels AG, Kleijnen J. 5% lidocaine medicated plaster in painful diabetic peripheral neuropathy (DPN): a systematic review. Swiss Med Wkly. 2010;140(21–22):297–306.
- Basit A, Basit KA, Fawwad A, Shaheen F, Fatima N, Petropoulos IN, et al. Vitamin D for the treatment of painful diabetic neuropathy. BMJ Open Diabetes Res Care. 2016;4(1):e000148. · DOI
- H.J. M. Placebo and control event rate. In: McQuay H.J., editor. Systematic reviews in pain research: methodology redefined. IASP Press, Seattle; 2008. pp. 51–6.
Cited by
Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy
Sloan, G., Selvarajah, D., & Tesfaye, S. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00496-z · Cited by 534
Self-citationBlonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Diabetic neuropathy: cutting-edge research and future directions
Yang, Y., Zhao, B., Wang, Y., Lan, H., Liu, X., Hu, Y., & Cao, P. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02175-1 · Cited by 234
“23 However, their use is limited by anticholinergic side effects, especially in elderly patients and those with cardiovascular disease.”
Diabetic neuropathy and neuropathic pain: a (con)fusion of pathogenic mechanisms?
Calcutt, N. A. (2020) · Pain · doi:10.1097/j.pain.0000000000001922 · Cited by 159
“In contrast to degenerative neuropathy, there are a number of therapies approved by regulatory agencies to alleviate pain in diabetes and others that are used off-label.(9,18) However, it is notable that none were developed to target diabetes-specific mechanisms, although efficacy is both unpredictable and restricted…”
BackgroundMethodManagement of diabetic neuropathy
Cernea, S., & Raz, I. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154867 · Cited by 115
Metadata
- Authors
- Alam, U., Sloan, G., & Tesfaye, S.
- Affiliations
- University of Liverpool (GB)
- Royal Hallamshire Hospital (GB)
- Corresponding author
- Alam, Uazman
- Venue
- Drugs
- Published
- 2020-02-10
- Volume
- 80
- Issue
- 4
- Pages
- 363-384
- ISSN
- 0012-6667 (ISSN-L)
- 1179-1950
- OpenAlex
- W3005601005
- Cited by
- 104
- References
- 249
- Citations by year
- 2026: 11 · 2025: 16 · 2024: 9 · 2023: 13 · 2022: 20 · 2021: 18 · 2020: 17
- FWCI
- 2.16
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Treatment
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Keywords
- painful diabetic polyneuropathy, neuropathic pain, pharmacotherapy, antidepressants, antiepileptic drugs, amitriptyline, duloxetine, gabapentin, pregabalin, tramadol, tapentadol, capsaicin, topical agents, new drugs, placebo response, treatment response biomarkers
- MeSH terms
- Anticonvulsants, Antidepressive Agents, Diabetic Neuropathies, Humans
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.